首页 > 最新文献

Leukemia & Lymphoma最新文献

英文 中文
Prospects for liquid biopsy approaches in lymphomas. 淋巴瘤液体活检方法的前景。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-10 DOI: 10.1080/10428194.2024.2389210
Esraa Jamal, Edward Poynton, Mohamed Elbogdady, Sameh Shamaa, Jessica Okosun

Analytes within liquid biopsies have emerged as promising alternatives to traditional tissue biopsies for various malignancies, including lymphomas. This review explores the clinical applications of one such liquid biopsy analyte, circulating tumor DNA (ctDNA) in different types of lymphoma, focusing on its role in diagnosis, disease monitoring, and relapse detection. Advancements in next-generation sequencing (NGS) and machine learning have enhanced ctDNA analysis, offering a multi-omic approach to understanding tumor genetics. In lymphoma, ctDNA provides insights into tumor heterogeneity, aids in genetic profiling, and predicts treatment response. Recent studies demonstrate the prognostic value of ctDNA and its potential to improve patient outcomes by facilitating early disease detection and personalized treatment strategies Despite these advancements, challenges remain in optimizing sample collection, processing, assay sensitivity, and overall consensus workflows in order to facilitate integration into routine clinical practice.

在包括淋巴瘤在内的各种恶性肿瘤中,液体活检分析物已成为传统组织活检的有前途的替代品。本综述探讨了循环肿瘤DNA(ctDNA)这种液体活检分析物在不同类型淋巴瘤中的临床应用,重点关注其在诊断、疾病监测和复发检测中的作用。下一代测序(NGS)和机器学习的进步加强了ctDNA分析,为了解肿瘤遗传学提供了一种多组学方法。在淋巴瘤中,ctDNA 可以帮助了解肿瘤的异质性,帮助进行基因图谱分析,并预测治疗反应。尽管取得了这些进展,但在优化样本采集、处理、检测灵敏度和整体共识工作流程方面仍存在挑战,以便将其纳入常规临床实践。
{"title":"Prospects for liquid biopsy approaches in lymphomas.","authors":"Esraa Jamal, Edward Poynton, Mohamed Elbogdady, Sameh Shamaa, Jessica Okosun","doi":"10.1080/10428194.2024.2389210","DOIUrl":"10.1080/10428194.2024.2389210","url":null,"abstract":"<p><p>Analytes within liquid biopsies have emerged as promising alternatives to traditional tissue biopsies for various malignancies, including lymphomas. This review explores the clinical applications of one such liquid biopsy analyte, circulating tumor DNA (ctDNA) in different types of lymphoma, focusing on its role in diagnosis, disease monitoring, and relapse detection. Advancements in next-generation sequencing (NGS) and machine learning have enhanced ctDNA analysis, offering a multi-omic approach to understanding tumor genetics. In lymphoma, ctDNA provides insights into tumor heterogeneity, aids in genetic profiling, and predicts treatment response. Recent studies demonstrate the prognostic value of ctDNA and its potential to improve patient outcomes by facilitating early disease detection and personalized treatment strategies Despite these advancements, challenges remain in optimizing sample collection, processing, assay sensitivity, and overall consensus workflows in order to facilitate integration into routine clinical practice.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1923-1933"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141913156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors and development of a predictive score model for tumor lysis syndrome in childhood leukemia: a 10-year experience from a single tertiary hospital in Thailand. 儿童白血病肿瘤溶解综合征的风险因素和预测评分模型的开发:泰国一家三级医院 10 年来的经验。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-18 DOI: 10.1080/10428194.2024.2390582
Pharsai Prasertsan, Edward B McNeil, Natsaruth Songthawee, Shevachut Chavananon, Pornpun Sripornsawan, Thampapon Chaisujyakorn, Thirachit Chotsampancharoen

Tumor lysis syndrome (TLS) in childhood leukemia was assessed retrospectively in 252 patients in a single tertiary center in Thailand during 2009-2019. Fifty-one (20.2%) developed TLS during their induction chemotherapy; 60.7% (31/51) were spontaneous TLS and 47% (24/51) developed clinical TLS. The predictive score model consisted of white blood cell (WBC) count more than 50,000 cells/mm3, glomerular filtration rate less than 90, and aspartate transaminase more than 44 units/L. The TLS development rates were 11.1%, 46.2%, and 78.5% in the low, intermediate, and high-risk groups, respectively. Death during the first induction phase in patients with TLS was significantly higher than in the patients without TLS. However, the 5-year overall survival rates for the children with and without TLS were not significantly different.

2009-2019年期间,泰国一家三级医疗中心对252名儿童白血病患者的肿瘤溶解综合征(TLS)进行了回顾性评估。51例(20.2%)患者在诱导化疗期间出现了TLS;60.7%(31/51)为自发性TLS,47%(24/51)为临床TLS。预测评分模型包括白细胞(WBC)计数大于 50,000 cells/mm3 、肾小球滤过率小于 90 和天门冬氨酸转氨酶大于 44 单位/L。低危、中危和高危组的 TLS 发生率分别为 11.1%、46.2% 和 78.5%。有TLS的患者在第一诱导阶段的死亡人数明显高于无TLS的患者。不过,有TLS和没有TLS的患儿的5年总生存率没有明显差异。
{"title":"Risk factors and development of a predictive score model for tumor lysis syndrome in childhood leukemia: a 10-year experience from a single tertiary hospital in Thailand.","authors":"Pharsai Prasertsan, Edward B McNeil, Natsaruth Songthawee, Shevachut Chavananon, Pornpun Sripornsawan, Thampapon Chaisujyakorn, Thirachit Chotsampancharoen","doi":"10.1080/10428194.2024.2390582","DOIUrl":"10.1080/10428194.2024.2390582","url":null,"abstract":"<p><p>Tumor lysis syndrome (TLS) in childhood leukemia was assessed retrospectively in 252 patients in a single tertiary center in Thailand during 2009-2019. Fifty-one (20.2%) developed TLS during their induction chemotherapy; 60.7% (31/51) were spontaneous TLS and 47% (24/51) developed clinical TLS. The predictive score model consisted of white blood cell (WBC) count more than 50,000 cells/mm<sup>3</sup>, glomerular filtration rate less than 90, and aspartate transaminase more than 44 units/L. The TLS development rates were 11.1%, 46.2%, and 78.5% in the low, intermediate, and high-risk groups, respectively. Death during the first induction phase in patients with TLS was significantly higher than in the patients without TLS. However, the 5-year overall survival rates for the children with and without TLS were not significantly different.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2009-2015"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting relapse in acute lymphoblastic leukemia. 预测急性淋巴细胞白血病的复发。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-31 DOI: 10.1080/10428194.2024.2387728
Marc S Schwartz, Lori S Muffly

Outcomes in adult and pediatric patients with acute lymphoblastic leukemia (ALL) have improved over successive generations due to rigorously conducted clinical trials and incorporation of novel therapeutic agents. Despite these advances, approximately 20% of high-risk pediatric patients and 50% of adults with ALL will fail to achieve long-term remission with frontline chemotherapy protocols, mostly due to relapse. The ability to predict which patients with ALL are more likely to relapse allows for early intensification of therapy and/or incorporation of novel immunotherapies with the goal of relapse prevention. In this review, we outline the most robust clinical predictors of relapse in ALL with a focus on measurable residual disease (MRD) and genomics. We also discuss application of these prognostic tools in different clinical settings including frontline treatment, pre-/post-allogeneic stem cell transplant, and pre-/post-Chimeric Antigen Receptor T-cell therapy.

由于进行了严格的临床试验并采用了新型治疗药物,成人和儿童急性淋巴细胞白血病(ALL)患者的治疗效果在一代又一代的患者身上得到了改善。尽管取得了这些进步,但仍有约 20% 的高风险儿科患者和 50% 的成人 ALL 患者无法通过一线化疗方案获得长期缓解,主要原因是复发。如果能够预测哪些ALL患者更有可能复发,就可以及早加强治疗和/或采用新型免疫疗法,从而达到预防复发的目的。在这篇综述中,我们概述了ALL复发的最可靠临床预测指标,重点是可测量残留疾病(MRD)和基因组学。我们还讨论了这些预后工具在不同临床环境中的应用,包括一线治疗、异体干细胞移植前后和嵌合抗原受体T细胞治疗前后。
{"title":"Predicting relapse in acute lymphoblastic leukemia.","authors":"Marc S Schwartz, Lori S Muffly","doi":"10.1080/10428194.2024.2387728","DOIUrl":"10.1080/10428194.2024.2387728","url":null,"abstract":"<p><p>Outcomes in adult and pediatric patients with acute lymphoblastic leukemia (ALL) have improved over successive generations due to rigorously conducted clinical trials and incorporation of novel therapeutic agents. Despite these advances, approximately 20% of high-risk pediatric patients and 50% of adults with ALL will fail to achieve long-term remission with frontline chemotherapy protocols, mostly due to relapse. The ability to predict which patients with ALL are more likely to relapse allows for early intensification of therapy and/or incorporation of novel immunotherapies with the goal of relapse prevention. In this review, we outline the most robust clinical predictors of relapse in ALL with a focus on measurable residual disease (MRD) and genomics. We also discuss application of these prognostic tools in different clinical settings including frontline treatment, pre-/post-allogeneic stem cell transplant, and pre-/post-Chimeric Antigen Receptor T-cell therapy.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1934-1940"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant? 基于 Venetoclax 的急性髓性白血病治疗:异基因造血干细胞移植道路上的意外收获?
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-23 DOI: 10.1080/10428194.2024.2381649
Francesco Tarantini, Cosimo Cumbo, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Giuseppina Tota, Angela Minervini, Crescenzio Francesco Minervini, Elisa Parciante, Maria Rosa Conserva, Immacolata Redavid, Giorgina Specchia, Pellegrino Musto, Francesco Albano

Despite the approval of new drugs, the inclusion of -omics-derived data and the integration of machine learning in both the diagnostic and therapeutic process, the prognosis of acute myeloid leukemia (AML) remains dismal. The curative path is still aimed at achieving a successful allogeneic hematopoietic stem cell transplant (HSCT) in most patients. Nevertheless, access to this procedure is limited to eligible patients. Moreover, post-HSCT outcomes are influenced by AML heterogeneity and patient-related factors. The rise of venetoclax (VEN)-based combinations as standard of care in the treatment of older or unfit AML patients, together with their peculiar management profile, has led researchers to evaluate the feasibility of this approach in patients proceeding toward HSCT. We reviewed the available evidence to weigh up the advantages and pitfalls of this new therapeutic strategy.

尽管新药已获批准,组学数据已被纳入,机器学习也已融入诊断和治疗过程,但急性髓性白血病(AML)的预后仍然不容乐观。大多数患者的治愈途径仍然是成功进行异基因造血干细胞移植(HSCT)。然而,只有符合条件的患者才有机会接受造血干细胞移植。此外,造血干细胞移植后的疗效还受到急性髓细胞性白血病异质性和患者相关因素的影响。以venetoclax(VEN)为基础的联合用药已成为治疗老年或体质不佳急性髓细胞白血病患者的标准疗法,再加上其特殊的管理模式,促使研究人员开始评估这种方法在进行造血干细胞移植的患者中的可行性。我们回顾了现有的证据,以权衡这种新治疗策略的优势和缺陷。
{"title":"Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?","authors":"Francesco Tarantini, Cosimo Cumbo, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Giuseppina Tota, Angela Minervini, Crescenzio Francesco Minervini, Elisa Parciante, Maria Rosa Conserva, Immacolata Redavid, Giorgina Specchia, Pellegrino Musto, Francesco Albano","doi":"10.1080/10428194.2024.2381649","DOIUrl":"10.1080/10428194.2024.2381649","url":null,"abstract":"<p><p>Despite the approval of new drugs, the inclusion of -omics-derived data and the integration of machine learning in both the diagnostic and therapeutic process, the prognosis of acute myeloid leukemia (AML) remains dismal. The curative path is still aimed at achieving a successful allogeneic hematopoietic stem cell transplant (HSCT) in most patients. Nevertheless, access to this procedure is limited to eligible patients. Moreover, post-HSCT outcomes are influenced by AML heterogeneity and patient-related factors. The rise of venetoclax (VEN)-based combinations as standard of care in the treatment of older or unfit AML patients, together with their peculiar management profile, has led researchers to evaluate the feasibility of this approach in patients proceeding toward HSCT. We reviewed the available evidence to weigh up the advantages and pitfalls of this new therapeutic strategy.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1777-1788"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia. 预测哪些骨髓增生异常肿瘤患者亚群更有可能发展为明显的慢性粒细胞白血病。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-14 DOI: 10.1080/10428194.2024.2378816
Violaine Tran Quang, Orianne Wagner-Ballon, Ivan Sloma

The boundary between myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) has been revised in the latest World Health Organization classification of myeloid malignancies. These changes were motivated by the description of a subgroup of MDS patients identified as oligomonocytic chronic myelomonocytic leukemia (OM-CMML) at risk of evolving into overt CMML. Various studies will be reviewed describing the clinical and biological features of MDS patients evolving to CMML. The efforts to discover biomarkers enabling the identification of these patients at the time of MDS diagnosis will be discussed. Finally, the molecular landscape of these patients will be presented with a specific focus on the biallelic inactivation of TET2 in light of its functional impact on hematopoietic stem cells, granule-monocytic differentiation, and its tight interplay with inflammation.

在世界卫生组织最新的骨髓恶性肿瘤分类中,骨髓增生异常综合征(MDS)和慢性粒细胞白血病(CMML)之间的界限已被修订。这些变化的起因是,MDS 患者中有一个亚群被认定为少单核细胞慢性粒细胞白血病(OM-CMML),有演变为明显的 CMML 的风险。我们将回顾各种研究,描述演变为 CMML 的 MDS 患者的临床和生物学特征。此外,还将讨论在 MDS 诊断时发现识别这些患者的生物标志物的工作。最后,将介绍这些患者的分子状况,并根据 TET2 对造血干细胞、粒-单核细胞分化的功能影响及其与炎症的密切相互作用,特别关注 TET2 的双偶性失活。
{"title":"Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia.","authors":"Violaine Tran Quang, Orianne Wagner-Ballon, Ivan Sloma","doi":"10.1080/10428194.2024.2378816","DOIUrl":"10.1080/10428194.2024.2378816","url":null,"abstract":"<p><p>The boundary between myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) has been revised in the latest World Health Organization classification of myeloid malignancies. These changes were motivated by the description of a subgroup of MDS patients identified as oligomonocytic chronic myelomonocytic leukemia (OM-CMML) at risk of evolving into overt CMML. Various studies will be reviewed describing the clinical and biological features of MDS patients evolving to CMML. The efforts to discover biomarkers enabling the identification of these patients at the time of MDS diagnosis will be discussed. Finally, the molecular landscape of these patients will be presented with a specific focus on the biallelic inactivation of <i>TET2</i> in light of its functional impact on hematopoietic stem cells, granule-monocytic differentiation, and its tight interplay with inflammation.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1766-1776"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationships, marriage, and partner abandonment among Hodgkin lymphoma survivors treated in nine EORTC-GELA Lymphoma Group trials. 在 EORTC-GELA 淋巴瘤小组的九项试验中接受治疗的霍奇金淋巴瘤幸存者的关系、婚姻和伴侣遗弃情况。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-12 DOI: 10.1080/10428194.2024.2390565
Sára Rossetti, Sidsel J Juul, Marleen A E van der Kaaij, Catherine Fortpied, Paul Meijnders, Berthe M P Aleman, John M M Raemaekers, Hanneke C Kluin-Nelemans, Michele Spina, Christophe Fermé, Loïc Renaud, Olivier Casasnovas, Aspasia Stamatoullas, Wouter J Plattel, Martin Hutchings, Maja V Maraldo
{"title":"Relationships, marriage, and partner abandonment among Hodgkin lymphoma survivors treated in nine EORTC-GELA Lymphoma Group trials.","authors":"Sára Rossetti, Sidsel J Juul, Marleen A E van der Kaaij, Catherine Fortpied, Paul Meijnders, Berthe M P Aleman, John M M Raemaekers, Hanneke C Kluin-Nelemans, Michele Spina, Christophe Fermé, Loïc Renaud, Olivier Casasnovas, Aspasia Stamatoullas, Wouter J Plattel, Martin Hutchings, Maja V Maraldo","doi":"10.1080/10428194.2024.2390565","DOIUrl":"10.1080/10428194.2024.2390565","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2035-2039"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. 对复发难治性多发性骨髓瘤患者进行的MEDI2228(一种BCMA靶向ADC)1期首次人体试验研究。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-15 DOI: 10.1080/10428194.2024.2373331
Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff, Farzana L Walcott, Nabendu Pore, Miranda Brown, Fujun Wang, Lily I Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yuling Wu, Yu Jiang, Robert J Kubiak, Jeffrey A Zonder, Jeremy Larsen, Shreerang Sirdesai, Andrew J Yee, Shaji Kumar

MEDI2228 is an antibody drug conjugate (ADC) comprised of a fully human B-cell maturation antigen (BCMA) antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer. This phase 1 trial evaluated MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma (MM), who received prior treatment with approved agents from 3 classes of antimyeloma drugs (proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies). Primary endpoint was safety and tolerability; secondary endpoints included efficacy, pharmacokinetics, and immunogenicity. A total of 107 patients were treated and the maximum tolerated dose (MTD) was 0.14 mg/kg Q3W. Two patients had dose-limiting toxicities (DLTs; thrombocytopenia; 0.20 mg/kg Q3W). The most frequent treatment-related adverse events were photophobia (43.9%), rash (29.0%), and thrombocytopenia (19.6%). In MTD cohort A (n = 41), the objective response rate (ORR) was 56.1%, with 1 stringent complete response, 9 very good partial responses, and 13 partial responses. ORR was 53.3% in triple refractory patients. In cohort B (n=25), ORR was 32%. Although MEDI2228 demonstrated efficacy in R/R MM, ocular toxicity precluded further development of this drug.

MEDI2228 是一种抗体药物共轭物 (ADC),由与吡咯并二氮卓 (PBD) 二聚体共轭的全人 B 细胞成熟抗原 (BCMA) 抗体组成。这项1期试验评估了MEDI2228在复发性/难治性(R/R)多发性骨髓瘤(MM)患者中的应用情况,这些患者之前接受过3类抗骨髓瘤药物(蛋白酶体抑制剂、免疫调节药物和单克隆抗体)的批准药物治疗。主要终点是安全性和耐受性;次要终点包括疗效、药代动力学和免疫原性。共有 107 名患者接受了治疗,最大耐受剂量(MTD)为 0.14 mg/kg Q3W。两名患者出现了剂量限制性毒性(DLT;血小板减少;0.20 mg/kg Q3W)。最常见的治疗相关不良事件是畏光(43.9%)、皮疹(29.0%)和血小板减少(19.6%)。在 MTD 队列 A(n = 41)中,客观应答率(ORR)为 56.1%,其中有 1 例严格完全应答、9 例非常好的部分应答和 13 例部分应答。三联难治性患者的客观应答率为 53.3%。在队列 B(25 人)中,ORR 为 32%。虽然 MEDI2228 对 R/R MM 有疗效,但眼部毒性阻碍了该药物的进一步开发。
{"title":"Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.","authors":"Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff, Farzana L Walcott, Nabendu Pore, Miranda Brown, Fujun Wang, Lily I Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yuling Wu, Yu Jiang, Robert J Kubiak, Jeffrey A Zonder, Jeremy Larsen, Shreerang Sirdesai, Andrew J Yee, Shaji Kumar","doi":"10.1080/10428194.2024.2373331","DOIUrl":"10.1080/10428194.2024.2373331","url":null,"abstract":"<p><p>MEDI2228 is an antibody drug conjugate (ADC) comprised of a fully human B-cell maturation antigen (BCMA) antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer. This phase 1 trial evaluated MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma (MM), who received prior treatment with approved agents from 3 classes of antimyeloma drugs (proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies). Primary endpoint was safety and tolerability; secondary endpoints included efficacy, pharmacokinetics, and immunogenicity. A total of 107 patients were treated and the maximum tolerated dose (MTD) was 0.14 mg/kg Q3W. Two patients had dose-limiting toxicities (DLTs; thrombocytopenia; 0.20 mg/kg Q3W). The most frequent treatment-related adverse events were photophobia (43.9%), rash (29.0%), and thrombocytopenia (19.6%). In MTD cohort A (<i>n</i> = 41), the objective response rate (ORR) was 56.1%, with 1 stringent complete response, 9 very good partial responses, and 13 partial responses. ORR was 53.3% in triple refractory patients. In cohort B (<i>n</i>=25), ORR was 32%. Although MEDI2228 demonstrated efficacy in R/R MM, ocular toxicity precluded further development of this drug.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1789-1800"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142469026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature. 成人T细胞白血病-淋巴瘤伴神经淋巴瘤病:一份病例报告和文献综述。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-25 DOI: 10.1080/10428194.2024.2381646
Masanori Toho, Megumi Yasunaga, Yasutaka Masuda, Arika Shimura, Yosuke Masamoto, Kensyo Sumi, Kyosuke Muramatsu, Masahiko Tsujita, Shuichiro Mitsuchi, Reo Yoshioka, Yusuke Baba, Hiroki Maekawa, Tomohiko Kimura, Masashi Hamada, Tatsushi Toda, Mineo Kurokawa
{"title":"Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature.","authors":"Masanori Toho, Megumi Yasunaga, Yasutaka Masuda, Arika Shimura, Yosuke Masamoto, Kensyo Sumi, Kyosuke Muramatsu, Masahiko Tsujita, Shuichiro Mitsuchi, Reo Yoshioka, Yusuke Baba, Hiroki Maekawa, Tomohiko Kimura, Masashi Hamada, Tatsushi Toda, Mineo Kurokawa","doi":"10.1080/10428194.2024.2381646","DOIUrl":"10.1080/10428194.2024.2381646","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1891-1895"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141759590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in location of death for individuals with acute myeloid leukemia in the United States. 美国急性髓性白血病患者死亡地点的变化趋势。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-27 DOI: 10.1080/10428194.2024.2382330
Urvish Jain, Faraan Rahim, Bhav Jain, Angelin Tresa Mathew, Erin Jay Garbes Feliciano, Edward Christopher Dee, Kaitlyn Lapen, Francis Lee, Fumiko Chino, Douglas Tremblay, Jennifer J Tsai
{"title":"Trends in location of death for individuals with acute myeloid leukemia in the United States.","authors":"Urvish Jain, Faraan Rahim, Bhav Jain, Angelin Tresa Mathew, Erin Jay Garbes Feliciano, Edward Christopher Dee, Kaitlyn Lapen, Francis Lee, Fumiko Chino, Douglas Tremblay, Jennifer J Tsai","doi":"10.1080/10428194.2024.2382330","DOIUrl":"10.1080/10428194.2024.2382330","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1905-1908"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1080/10428194.2024.2432582
Fausto Alfredo Rios-Olais, Sergio Rodriguez-Rodriguez, Analy Mora-Cañas, Christian Omar Ramos-Peñafiel, Victor Itaí Urbalejo-Ceniceros, Yadith Karina Lopez-Garcia, Andres Gomez-De Leon, Nancy Delgado-Lopez, Mistral Castellanos-Mares, Patricia Carolina Figueroa-Hernandez, Roberta Demichelis-Gomez
{"title":"Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.","authors":"Fausto Alfredo Rios-Olais, Sergio Rodriguez-Rodriguez, Analy Mora-Cañas, Christian Omar Ramos-Peñafiel, Victor Itaí Urbalejo-Ceniceros, Yadith Karina Lopez-Garcia, Andres Gomez-De Leon, Nancy Delgado-Lopez, Mistral Castellanos-Mares, Patricia Carolina Figueroa-Hernandez, Roberta Demichelis-Gomez","doi":"10.1080/10428194.2024.2432582","DOIUrl":"https://doi.org/10.1080/10428194.2024.2432582","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-4"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Leukemia & Lymphoma
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1